指南与共识前列腺癌

指南之指南:局限或局部晚期前列腺癌的原发单药治疗

Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer.
指南 / 共识 · BJU Int · 2018-05-01

该综述系统比较了12个组织发布的14部前列腺癌原发治疗指南,发现各指南对「局限」前列腺癌的定义及风险分层存在差异,导致主动监测、近距离放疗和外照射放疗推荐不一致,而根治性前列腺切除术和激素治疗推荐基本一致。

要点

  • 多数指南将局限前列腺癌定义为cT1-cT3,但部分定义为cT1-cT2或任何T期但N0M0。
  • 风险分层差异是主动监测、近距离放疗和外照射放疗推荐不一致的主要原因。
  • 根治性前列腺切除术和激素治疗推荐在各指南间基本一致。

核心结论

  • 各国际指南对局限前列腺癌的定义和风险分层不一致,导致部分原发治疗推荐存在差异。

研究设计与样本

  • 系统检索Medline、美国国家指南交换中心、国际指南网络图书馆及主要泌尿协会网站,纳入12个组织的14部指南。

主要发现

  • 局限前列腺癌定义在多数指南为cT1-cT3,其他指南为cT1-cT2或任何T期但无淋巴结转移(N0)和无转移(M0)。
  • 局限癌风险分层在各指南间差异显著。
  • 根治性前列腺切除术和激素治疗推荐基本一致,主动监测、近距离放疗和外照射放疗推荐各异。

临床怎么用

  • 临床解读前列腺癌原发治疗指南时需注意其局限癌定义和风险分层体系,避免跨指南直接套用推荐。

局限性

  • 指南发表年份和方法学(共识制或证据制)不同可能部分解释推荐差异。
  • 国际临床实践差异可能部分源于指南推荐不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Decisions regarding the primary treatment of prostate cancer depend on several patient- and disease-specific factors. Several international guidelines regarding the primary treatment of prostate cancer exist; however, they have not been formally compared. As guidelines often contradict each other, we aimed to systematically compare recommendations regarding the different primary treatment modalities of prostate cancer between guidelines. We searched Medline, the National Guidelines Clearinghouse, the library of the Guidelines International Network, and the websites of major urological associations for prostate cancer treatment guidelines. In total, 14 guidelines from 12 organisations were included in the present article. One of the main discrepancies concerned the definition of 'localised' prostate cancer. Localised prostate cancer was defined as cT1-cT3 in most guidelines; however, this disease stage was defined in other guidelines as cT1-cT2, or as any T-stage as long as there is no lymph node involvement (N0) or metastases (M0). In addition, the risk stratification of localised cancer differed considerably between guidelines. Recommendations regarding radical prostatectomy and hormonal therapy were largely consistent between the guidelines. However, recommendations regarding active surveillance, brachytherapy, and external beam radiotherapy varied, mainly as a result of the inconsistencies in the risk stratification. The differences in year of publication and the methodology (i.e. consensus-based or evidence-based) for developing the guidelines might partly explain the differences in recommendations. It can be assumed that the observed variation in international clinical practice regarding the primary treatment of prostate cancer might be partly due to the inconsistent recommendations in different guidelines.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Lancee M, Tikkinen KAO, de Reijke TM, et al. Guideline of guidelines: primary monotherapies for localised or locally advanced prostate cancer. BJU Int. 2018. PMID: 29633514. doi:10.1111/bju.14237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。